Buy Vivitrol

Intramuscularly, into the buttock muscle, alternating buttocks.

 

The recommended dose of Vivitrol is 380 mg intramuscularly 1 time in 4 weeks or 1 time in a month.

 

Vivitrol can't be injected intravenously!

 

If the patient misses the next dose, the next injection should be given as soon as possible. Oral administration of naltrexone is not required before Vivitrol is administered.

 

Resumption of treatment after a break.
There are no data available on the resumption of treatment after the break.

 

Transferring alcohol-dependent patients from oral naltrexone to Vivitrol
No systematic data on the transfer of patients with oral naltrexone to Vivitrol.

 

 

 

Only the supplied solvent should be used for preparing the suspension. 

The drug should only be injected with the supplied needle. 

All components of the packaging - powder vial, solvent vial, suspension preparation needle and injection needle with protective cap - are necessary for the preparation.

A spare injection needle with protective cap is also included.

The components included in the set should not be replaced.

In order to ensure accurate dosing, the instructions for preparation and administration of the preparation should be clearly followed. Aseptic rules must be followed.

 

 

1. Suspension preparation kit composition

 

• 1 vial with solvent;

 

• 1 vial with powder;

 

• 1 disposable syringe;

 

• 2 needles for injection with protective cap;

 

• 1 short needle for suspension preparation.

 

2. Procedure for the preparation of the suspension

 

- Before use, take the product pack out of the fridge and let it warm up to room temperature (approx. 45 min);

 

- for easy mixing, knock the tip of the powder bottle on a hard surface to open the powder;

 

- remove the aluminium caps from both vials (do not use the product if the vial caps are damaged or missing);

 

- wipe the necks of the bottles with an alcoholic cloth;

 

- put a short suspension needle on the syringe and remove 3.4 ml of solvent from the solvent bottle (some amount of solvent will remain in the bottle);

 

- inject 3.4 ml of solvent into the powder bottle;

 

- mix solvent and powder by shaking the vial intensively for approx. 1 min. Before continuing, make sure that the suspension is homogeneous. A properly mixed slurry must be milky white, free of lumps and flow down the walls of the vial.

 

3. Suspension filling order

 

- Immediately after preparation, remove 4.2 ml of suspension in a syringe using a suspension needle;
 

- take that needle off and put an injection needle on the syringe;

 

- before the injection, knock on the syringe to release air bubbles, then gently press the piston until there is 4 ml of suspension left in the syringe. The suspension is ready for immediate injection.

 

 

Procedure of injection of suspension

 

- The needle of the syringe is injected deep into the buttock muscle; after that, the suction movement of the piston checks if the needle has got into the vessel (if it has got into the syringe, blood is thrown into it). If there is blood, the procedure should be repeated by replacing the needle with a spare one;
 

- the drug is injected in a gentle movement deep into the buttock muscle. The suspension is injected alternately in different buttocks.

 

Vivitrol cannot be injected intravenously or subcutaneously.

 

 

Disposal of used and unused packaging components

 

- after injection, close the needle with the protective cap, pressing it with one hand against a solid surface and holding it in the direction of the needle (using the protective cap prevents splashing of liquid that may remain on the needle after injection);

 

- dispose of used and unused packaging components.

The overdose data is very limited. A single dose of 784 mg was administered to 5 healthy volunteers. They had no serious side effects.

 

Symptoms: 

the most common side effects were reactions at the injection site, nausea, abdominal pain, drowsiness and dizziness. No significant increase in the activity of hepatic enzymes was observed.

 

Treatment:

Supporting therapy.

• patients who are taking drug analgesics;

 

• while taking opioids against the background of drug treatment;

 

• patients with acute opioid withdrawal (opioid withdrawal syndrome);

 

• patients who have not undergone a provocative naloxone test or have a positive urine opioid test;

 

• patients who are hypersensitive to the drug substance or any of its fillers and solvent components;

 

• patients with severe liver function disorders (including acute hepatitis and liver failure);

 

• during pregnancy and lactation;

 

• children under 18 years of age.

 

Cautiously

 

Use in cases of liver insufficiency:

 

Patients with mild to moderate liver dysfunction (Child-Pugh grades A and B) do not require dose correction. Patients with severe liver dysfunction have not studied the pharmacokinetics of Vivitrol. Such patients, like all other Vivitrol injections, should be administered with caution due to the risk associated with the Vivitrol injection (e.g. thrombocytopenia and coagulation disorders).

 

Application in case of renal failure:

 

Patients with mild renal failure (Cl creatinine 50-80 ml/min) do not require dose correction. Vivitrol pharmacokinetics has not been studied in patients with moderate and severe renal insufficiency. Since naltrexone and its primary metabolite are mainly excreted in the urine, it is recommended to prescribe Vivitrol with caution to patients with moderate or severe renal failure.​​​​​​​

Side effects, in alcohol-dependent patients

 

They were encountered in clinical trials in more than 5% of cases (often), the severity of these side effects was characterized as mild and moderate.

 

GIT:

 

nausea, vomiting, diarrhoea, frequent defecation urges, gastrointestinal disorder, frequent liquid stools, abdominal pain, stomach discomfort, dry mouth, anorexia, reduced appetite, impaired appetite.

 

Respiratory system:

 

Upper respiratory tract infections, laryngitis, sinusitis, pharyngitis (including streptococcal), nasopharyngitis.

 

Common disorders and reactions at the injection site:

 

Pain, sickness, thickening, swelling, itching, bleeding, asthenia, lethargy, dullness.

 

Musculoskeletal system:

 

Arthritis, joint pain, joint stiffness, back pain, pain in the extremities, muscle spasm, muscle twitching, muscle stiffness.

 

Skin and hypodermis:

 

Rashes, papule rashes, sweat.

 

Nervous system:

 

Headache, migraine, dizziness, fainting, drowsiness, anxiety, sedation.

 

 

Side effects in opioid-dependent patients

 

Laboratory indicators:

increase in ALT (alanine transfer), AST (aspartate transfer) and GGT (gamma-glutamyl transfer) activity.

 

Respiratory system:

nasopharyngitis, influenza.

Nervous system:

insomnia, headache.

Cardiovascular system:

increase in BP (blood pressure).

 

General disorders and reactions at the injection site:

pain.

 

GIT:

toothache.

 

 

Side effects detected during pre-registration trials of the drug

 

Gastrointestinal tract:

 

perversion of taste, increased appetite, reflux esophagitis, constipation, flatulence, hemorrhoids, colitis, gastrointestinal bleeding, paralytic bowel obstruction, pararectal abscess, gastroenteritis, tooth abscess, abdominal discomfort, acute pancreatitis.

 

General disorders and reactions at the place of administration:

 

fever, lethargy, chest pain, tightness in the chest, increase or decrease in body weight, tremors, chills, swelling of the face.

 

Mental disorders:

 

irritability, sleep disturbance, alcohol withdrawal syndrome, agitation, euphoria, delirium.

 

Nervous system:

 

attention deficit, migraine, decreased mental activity, cramps, ischemic stroke, cerebral artery aneurysms, paresthesia.

Senses:

 

blurred vision, conjunctivitis.

 

The musculoskeletal system:

 

pain in the extremities, muscle spasm, stiffness in the joints, myalgia.

 

Skin and hypodermis:

 

intense sweating, including at night, itching.

 

Respiratory system:

 

sore throat, shortness of breath, nasal congestion, obstructive bronchitis, bronchitis, pneumonia, laryngitis, sinusitis, upper respiratory tract infections.

 

Metabolism:

 

heat stroke, dehydration, hypercholesterolemia.

 

Cardiovascular System:

 

tides, deep vein thrombosis, pulmonary thrombosis, rapid heartbeat, atrial fibrillation, myocardial infarction, angina, unstable angina, chronic heart failure, coronary artery atherosclerosis.

 

Blood and lymphatic system:

 

lymphadenopathy, including inflammation of cervical lymph nodes, increased white blood cell count.

 

The immune system:

 

seasonal allergy, hypersensitivity reactions, including angioedema and urticaria, HIV infection progression in HIV-infected patients.

 

Urogenital system:

 

spontaneous abortion, decreased libido, urinary tract infections.

 

Hepatobiliary system:

 

cholelithiasis, increase in ALT and AST activity, acute cholecystitis.

Vivitrol is used to block opioid receptors in the brain. Naltrexone is similar in structure to drugs, but it is not a drug. On the contrary, Naltrexone binds to the opioid receptors inside the brain, so that neither drugs nor alcohol can lead to intoxication. Thus, by using drugs or alcohol, a person will feel absolutely nothing, no "high" and no relaxation. As a result, a completely different attitude to drugs or alcohol will be gradually formed, and the person will no longer treat them as sources of pleasure. 

The action of the drug is not limited by a short period of time - Vivitrol (Naltrexone), injected into the patient's body remains effective for about 21 days. At the end of the drug cycle, it is necessary to repeat the administration of Vivitrol into the human body. The use of Vivitrol can be effective only in combination with psychotherapeutic effect and requires repeated use of Vivitrol to obtain a persistent positive result.

• the first injections are already reducing the urge for alcoholic drinks;

 

• after the therapy, alcoholism is cured in 79% of people who regularly drink alcohol, in the remaining 21% of cases, significantly reduce the duration of drinking, on average by 3.5 times compared to the beginning of therapy

 

• has minimal side effects, unlike other drugs for alcohol treatment;

 

• the product does not cause unpleasant sensations after drinking alcohol;

 

• after the first days of therapy, alcohol does not give the euphoria for which a person drinks;

 

• opiate addiction is reduced by half after the second injection and remains stable;

 

• Vivitrol therapy provides recovery of performance, social connections and stabilization of the patient's emotional state.

 

Although alcohol-containing drinks do not cause unpleasant effects during therapy, drinking is not recommended. This has a direct impact on the effectiveness of treatment.

Powder: naltrexone encapsulated in a copolymer of lactic and glycolic acid (polymer: 75:25 DL JN1). The bottle contains 430 mg of naltrexone (excess 12.9%).

 

Solvent: sodium carmellose (sodium carboxymethylcellulose), polysorbate 20, sodium chloride, water for injection. The bottle contains 4.0 ml of solvent.

Full Prescribing Information on English

You can buy Vivitrol from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Vivitrol without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Vivitrol on our website without prescription!